TL-925

Phase 2Small molecule

TTelios Pharma, Inc.

TL-925 is one of 58 small molecule programs targeting Allergic Conjunctivitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Allergic ConjunctivitisActive, not recruiting

Eye DiseaseActive, not recruiting

Allergic ConjunctivitisPhase 2

Active, not recruiting

Eye DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

200 competitors in Eye Disease

#DrugCompanyPhaseTrials

Neoral

Novartis

Phase 3

2 2

Chantix

Pfizer

Phase 3

2 3

Bayer Aspirin

Bayer

Phase 3

1 4

Zovirax

BBp Consulting, Inc

Phase 3

2 5

CF101

CCan-Fite BioPharma

Phase 3

1 6

Refresh Plus

AbbVie

Phase 3

1 7

Csa

ZZhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.

Phase 3

1 8

Cenegermin

DDompé Farmaceutici S.p.A

Phase 3

1 9

Diquafosol Tetrasodium

Merck & Co.

Phase 3

3 10

REFRESH LIQUIGEL

AbbVie

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Allergic Conjunctivitis3 trials

A Study of TL-925 for the Treatment of Allergic Conjunctivitis

Unknown status·TTelios Pharma, Inc.·Phase 2·NCT06153342·70 enrolled

Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis

Recruiting·TTelios Pharma, Inc.·Phase 2·NCT07220408·60 enrolled

Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis

Recruiting·TTelios Pharma, Inc.·Phase 2·NCT06686472·66 enrolled

Eye Disease2 trials

A Study of TL-925 as a Treatment for Dry Eye Disease

Completed·TTelios Pharma, Inc.·Phase 2·NCT05745064·107 enrolled

A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease

Active, not recruiting·TTelios Pharma, Inc.·Phase 2·NCT06225973·880 enrolled

Treatment1 trial

A Study Of TL-925 For The Treatment of AC

Completed·TTelios Pharma, Inc.·Phase 2·NCT06293820·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for TL-925. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TL-925 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TL-925. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Telios Pharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTelios Pharma, Inc.

TL-925

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Allergic Conjunctivitis3 trials

Eye Disease2 trials

Treatment1 trial

References

Drug Info

Quick Facts

Related News